Senores Pharmaceuticals provided comprehensive updates during its recent conference call, addressing strategic revenue positioning, acquisition-related cost implications, and significant revenue projections from its new manufacturing facility.

New Plant Revenue Projections

During the conference call, company management outlined ambitious revenue targets for their new manufacturing plant. The management indicated that in its first year of operation, the new facility could contribute ₹100-120 crores in revenue with an impressive 30% EBITDA margin during the period spanning FY26-27.

Apnar Plant Acquisition Cost Outlook

The pharmaceutical company's management clarified that they do not anticipate any significant increase in operational costs following the Apnar plant acquisition. This guidance provides clarity on the financial impact of the strategic acquisition on the company's cost structure, ensuring operational efficiency remains intact.

Strategic Focus on Regulated Markets

Management also indicated during the conference call that they expect to see a shift in their revenue composition, with regulated markets anticipated to contribute a larger portion of total revenues going forward. This development represents a strategic positioning for the company in markets with stricter regulatory frameworks.

Growth Strategy and Market Positioning

Regulated markets typically refer to regions with stringent pharmaceutical regulations and approval processes, such as the United States, European Union, and other developed markets. These markets generally offer better pricing power and margins compared to semi-regulated or unregulated markets. The combination of new plant capacity and regulated market focus demonstrates the company's commitment to sustainable, profitable growth.

Senores Pharmaceuticals' strategic approach combines capacity expansion through new manufacturing facilities with market positioning in high-value regulated segments, while maintaining strict cost discipline across operations.

Senores Pharmaceuticals Limited has announced a strategic acquisition that will expand its pharmaceutical manufacturing capabilities. The company's Management Committee of the Board of Directors approved the acquisition of Apnar Pharma Private Limited on December 15, 2025, marking a significant step in the company's growth strategy.

Acquisition Structure and Timeline

Senores Pharmaceuticals has announced the acquisition of a 100% stake in Apnar Pharma Private Limited for a total enterprise value of ₹91.00 crores. The acquisition will be completed in two tranches by Q2 FY2027, with Apnar Pharma becoming a wholly owned subsidiary upon completion.

Financial Structure

The deal structure combines cash payments with debt and liability assumptions, providing a balanced approach to the acquisition financing. The total consideration reflects the strategic value of acquiring established pharmaceutical manufacturing capabilities.

Manufacturing Facility Specifications

The acquired facility in Jambusar, Gujarat represents a state-of-the-art pharmaceutical manufacturing operation that commenced in 2021. The facility received USFDA approval in September 2022 and maintains multiple international regulatory certifications.

Production Capacity and Market Reach

The facility demonstrates significant production capabilities across multiple dosage forms with expansion potential. Current operations serve regulated markets including the US, UK, and Canada.

Target Company Profile

Apnar Pharma Private Limited brings significant manufacturing credentials to the acquisition. The company was incorporated in Gujarat on December 12, 2014, under the Companies Act, 2013, and has established itself as a manufacturer of generic pharmaceutical formulations.

Key operational highlights include:

• USFDA approved manufacturing facility
• UK-MHRA certification
• Health Canada approval
• Manufacturing facility located in Jambusar, Gujarat
• Focus on generic pharmaceutical formulations
• Strong R&D and analytical capabilities

Financial Performance Track Record

Apnar Pharma's revenue performance over the past three years demonstrates the operational scale of the acquisition target.

Strategic Rationale and Synergies

The acquisition provides immediate access to regulated markets including UK and Canada, expanding beyond Senores Pharmaceuticals' current US presence. The deal includes 5 approved ANDAs representing a total market opportunity exceeding $700 million.

According to Swapnil Shah, Promoter Managing Director, the acquisition will enable the company to manufacture select US products from India, improving operational leverage and supporting margin expansion. The facility will strengthen manufacturing capabilities and deepen customer relationships, creating opportunities in the CDMO and CMO segments.

Key strategic benefits include:

• Enhanced market access across regulated territories
• Revenue and cost synergies through cross-selling
• Backward integration via in-house manufacturing
• Improved supply chain control and regulatory compliance
• Expansion of product portfolio and customer penetration

ANDA Portfolio Acquisition

In addition to the facility acquisition, Senores Pharmaceuticals Inc., the company's wholly owned subsidiary, is acquiring a basket of 5 ANDAs from Apnar Pharma's parent company. Of these 5 ANDAs, 3 are validated and qualified, with commercialization expected to begin immediately.

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with regulatory requirements.